<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02910778</url>
  </required_header>
  <id_info>
    <org_study_id>FBF-Statin-Tica</org_study_id>
    <nct_id>NCT02910778</nct_id>
  </id_info>
  <brief_title>The Effect of Ticagrelor With or Without Atorvastatin on Endothelial Function in Healthy Males</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Effect of Atorvastatin Treatment for 14 Days in Combination With an Acute Dose of Ticagrelor on Ischemia Reperfusion Induced Endothelial Dysfunction of the Forearm Vasculature in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To test the effect of atorvastatin or placebo in combination with ticagrelor on ACh-induced
      vasodilatation of the forearm resistance vasculature as assessed by forearm blood flow (FBF)
      measurement before and 10 min after a 20 min forearm ischemia. The area under the dose-effect
      curve (AUC) of different ACh doses will be calculated and compared between treatment groups
      (atorvastatin + ticagrelor vs. placebo + ticagrelor) and different time points (pre-ischemia
      vs. post-ischemia).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2016</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">February 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the curve (AUC) of Forearm blood flow (FBF) measurements of Acetylcholine (ACh) induced vasodilatation</measure>
    <time_frame>Change of the AUC before and 10 min after forearm ischemia</time_frame>
    <description>To test the effect of atorvastatin or placebo in combination with ticagrelor on ACh-induced vasodilatation of the forearm resistance vasculature as assessed by FBF measurement before and 10 min after a 20 min forearm ischemia</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the curve (AUC) of Forearm blood flow (FBF) measurements of Glyceryltrinitrate (GTN) induced vasodilatation</measure>
    <time_frame>Change of the AUC before and 10 min after forearm ischemia</time_frame>
    <description>To test the effect of atorvastatin or placebo in combination with ticagrelor on GTN-induced vasodilatation of the forearm resistance vasculature as assessed by FBF measurement before and 10 min after a 20 min forearm ischemia</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Ischemia</condition>
  <arm_group>
    <arm_group_label>Atorvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>80 mg atorvastatin for 14 days with a loading dose of 180 mg ticagrelor on day 15</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for 14 days with a loading dose of 180 mg ticagrelor on day 15</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>Subjects will receive 80 mg atorvastatin once daily for 14 days (until study day 15). On study day 15, 80 mg atorvastatin in combination with a loading dose of 180 mg ticagrelor will be administered.</description>
    <arm_group_label>Atorvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects will receive placebo once daily for 14 days (until study day 15). On study day 15, placebo in combination with a loading dose of 180 mg ticagrelor will be administered.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <arm_group_label>Atorvastatin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male subjects; 18 - 40 years of age

          -  Body mass index between 18 and 27 kg/m2

          -  Written informed consent

          -  Normal findings in medical &amp; bleeding history

          -  Non-smoking

        Exclusion Criteria:

          -  Regular intake of any medication including OTC drugs and herbals within 2 weeks before
             IMP administration

          -  Known coagulation disorders (e.g. haemophilia, von WillebrandÂ´s disease)

          -  Known disorders with increased bleeding risk (e.g. peridontosis, haemorrhoids, acute
             gastritis, peptic ulcer, intestinal ulcer)

          -  Known sensitivity to common causes of bleeding (e.g. nasal)

          -  History of thromboembolism

          -  History of occlusive vascular diseases

          -  History of vascular anomalies

          -  History of hypercholesterolemia

          -  History of myopathy

          -  Impaired liver function (AST, ALT, gGT, bilirubin &gt; 3 x ULN)

          -  Impaired renal function (serum creatinine &gt; 1.3 mg/dl)

          -  Elevated creatinine-kinase or serum-myoglobin (&gt; 3 x ULN)

          -  Any other relevant deviation from the normal range in clinical chemistry, haematology
             or urine analysis

          -  HIV-1/2-Ab, HbsAg or HCV-Ab positive serology

          -  Systolic blood pressure above 145 mmHg, diastolic blood pressure above 95 mmHg

          -  Known allergy against any test agent under study

          -  Regular daily consumption of more than on litre of xanthine-containing beverages or
             more than 40g alcohol

          -  Participation in another clinical trial during the preceding 3 weeks
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Medical University of Vienna, Department of Clinical Pharmacology</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 19, 2016</study_first_submitted>
  <study_first_submitted_qc>September 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2016</study_first_posted>
  <last_update_submitted>March 21, 2017</last_update_submitted>
  <last_update_submitted_qc>March 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Michael Wolzt, Prof. MD</investigator_full_name>
    <investigator_title>Prof. MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

